Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;55(1):232-9.
doi: 10.3349/ymj.2014.55.1.232.

Comprehensive variant screening of the UGT gene family

Jason Yongha Kim  1 , Hyun Sub Cheong, Byung Lae Park, Lyoung Hyo Kim, Suhg Namgoong, Ji On Kim, Hae Deun Kim, Young Hoon Kim, Myeon Woo Chung, Soon Young Han, Hyoung Doo Shin
Affiliations

Comprehensive variant screening of the UGT gene family

Jason Yongha Kim et al. Yonsei Med J. 2014 Jan.

Abstract

Purpose: UGT1A1, UGT2B7, and UGT2B15 are well-known pharmacogenes that belong to the uridine diphosphate glucuronyltransferase gene family. For personalized drug treatment, it is important to study differences in the frequency of core markers across various ethnic groups. Accordingly, we screened single nucleotide polymorphisms (SNPs) of these three genes and analyzed differences in their frequency among five ethnic groups, as well as attempted to predict the function of novel SNPs.

Materials and methods: We directly sequenced 288 subjects consisting of 96 Korean, 48 Japanese, 48 Han Chinese, 48 African American, and 48 European American subjects. Subsequently, we analyzed genetic variability, linkage disequilibrium (LD) structures and ethnic differences for each gene. We also conducted in silico analysis to predict the function of novel SNPs.

Results: A total of 87 SNPs were detected, with seven pharmacogenetic core SNPs and 31 novel SNPs. We observed that the frequencies of UGT1A1 *6 (rs4148323), UGT1A1 *60 (rs4124874), UGT1A1 *93 (rs10929302), UGT2B7 *2 (rs7439366), a part of UGT2B7 *3 (rs12233719), and UGT2B15 *2 (rs1902023) were different between Asian and other ethnic groups. Additional in silico analysis results showed that two novel promoter SNPs of UGT1A1 -690G>A and -689A>C were found to potentially change transcription factor binding sites. Moreover, 673G>A (UGT2B7), 2552T>C, and 23269C>T (both SNPs from UGT2B15) changed amino acid properties, which could cause structural deformation.

Conclusion: Findings from the present study would be valuable for further studies on pharmacogenetic studies of personalized medicine and drug response.

Keywords: SNP; UGT1A1; UGT2B15; UGT2B7; personalized medicine; uridine diphosphate glucuronyltransferase.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

References

    1. King CD, Rios GR, Green MD, Tephly TR. UDP-glucuronosyltransferases. Curr Drug Metab. 2000;1:143–161. - PubMed
    1. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol. 2001;21:500–515. - PubMed
    1. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002;99:16093–16098. - PMC - PubMed
    1. Lacko M, Voogd AC, Roelofs HM, te Morsche RH, Oude Ophuis MB, Peters WH, et al. Combined effect of genetic polymorphisms in phase I and II biotransformation enzymes on head and neck cancer risk. Head Neck. 2013;35:858–867. - PubMed
    1. Bajro MH, Josifovski T, Panovski M, Jankulovski N, Nestorovska AK, Matevska N, et al. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet. 2012;205:163–167. - PubMed

Publication types

Substances